Dark Forest Capital Management LP Takes $540,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

Dark Forest Capital Management LP acquired a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,530 shares of the biotechnology company's stock, valued at approximately $540,000.

Several other large investors have also added to or reduced their stakes in UTHR. Wealthfront Advisers LLC increased its stake in United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after buying an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. increased its position in shares of United Therapeutics by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock valued at $1,567,253,000 after acquiring an additional 32,213 shares during the last quarter. FMR LLC raised its holdings in United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after acquiring an additional 393,777 shares in the last quarter. Geode Capital Management LLC raised its holdings in United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock worth $401,184,000 after acquiring an additional 44,277 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in United Therapeutics by 28.5% during the fourth quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company's stock valued at $250,179,000 after purchasing an additional 157,363 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Trading Down 1.2 %

Shares of NASDAQ:UTHR traded down $3.69 during trading on Wednesday, reaching $297.07. 412,766 shares of the stock were exchanged, compared to its average volume of 448,156. The firm has a market cap of $13.34 billion, a PE ratio of 13.05, a PEG ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 12 month low of $233.31 and a 12 month high of $417.82. The stock has a 50-day moving average price of $305.66 and a 200-day moving average price of $345.68.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.17 EPS. On average, sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 74,500 shares of company stock worth $24,472,050 in the last quarter. 11.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on UTHR shares. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target on the stock in a research report on Monday, April 21st. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Finally, HC Wainwright reiterated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $390.17.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.